방기황기탕의 유전자 다형성에 따른 비만 치료 효과 : 무작위 배정, 이중 맹검, 위약-대조군 임상시험 (Impact of GNB3, ADRB3, UCP2, and PPARγ-Pro12Ala polymorphisms on Boiogito response in obese subjects : A randomized, double-blind, placebo-controlled trial)

서지정보

· 발행기관 : 한방비만학회
· 수록지 정보 : 한방비만학회지 / 12권 / 2호 / 28 ~ 43페이지
· 저자명 : 박정현, BOSE, 임지연, 김호준

초록

ObjectivesThe aim of the study was to investigate the efficacy of Boiogito for obesity. We examined the efficacy of boiogito for obese patients and we expected the reaction of Boiogito would vary according to the single uncleotide polymorphism(SNPs).
Methods111 subjects(body mass index≥25m/kg²) were recruited and randomized to receive Boiogito(n=55) or Placebo(n=55) for 8weeks. Anthropometric factors, serum lipid profile, glucose, blood pressure(BP), pulse rate, resting metabolic rate and Koran version of obesity-related quality of life(KOQOL) scale measured at baseline and 8weeks.
SNPs(ß3-adrenegic receptor(ADRB3), G protein ß3(GNB3), peroxisome proliferator activated receptor gamma 2 gene(PPAR-ɤ2), uncoupling protein(UCP2)) were conducted at baseline. Adverse reactions and safety outcome variables were also checked during trials.
ResultsBoth groups showed significant improvement on obesity after treatment. Boiogito group decreased triglyceride then did control group and improved KOQOL. Boiogito showed a significant higher efficacy in C/T and T/T genotype of GNB3 gene / in Trp64 and Arg64 genotype of ADRB3 gene / in D/D genotype of UCP2 gene / in Pro/Pro genotype of PPAR-γ gene.
ConclusionsBoiogito promoted obesity indexes without severe adverse reactions and proved its safety. Pharmacogenetical studies of Boiogito on obesity could be a effective method for the individualized treatment and prevention of obesity.

영어초록

ObjectivesThe aim of the study was to investigate the efficacy of Boiogito for obesity. We examined the efficacy of boiogito for obese patients and we expected the reaction of Boiogito would vary according to the single uncleotide polymorphism(SNPs).
Methods111 subjects(body mass index≥25m/kg²) were recruited and randomized to receive Boiogito(n=55) or Placebo(n=55) for 8weeks. Anthropometric factors, serum lipid profile, glucose, blood pressure(BP), pulse rate, resting metabolic rate and Koran version of obesity-related quality of life(KOQOL) scale measured at baseline and 8weeks.
SNPs(ß3-adrenegic receptor(ADRB3), G protein ß3(GNB3), peroxisome proliferator activated receptor gamma 2 gene(PPAR-ɤ2), uncoupling protein(UCP2)) were conducted at baseline. Adverse reactions and safety outcome variables were also checked during trials.
ResultsBoth groups showed significant improvement on obesity after treatment. Boiogito group decreased triglyceride then did control group and improved KOQOL. Boiogito showed a significant higher efficacy in C/T and T/T genotype of GNB3 gene / in Trp64 and Arg64 genotype of ADRB3 gene / in D/D genotype of UCP2 gene / in Pro/Pro genotype of PPAR-γ gene.
ConclusionsBoiogito promoted obesity indexes without severe adverse reactions and proved its safety. Pharmacogenetical studies of Boiogito on obesity could be a effective method for the individualized treatment and prevention of obesity.

참고자료

· 없음